Document:

Form of Stock Award Agreement

 Exhibit 10.1 
 Learning Tree International, Inc. 
 STOCK AWARD
AGREEMENT 
 To: [name of Grantee] (“Grantee”) 
 From: Learning Tree International, Inc. 
 “Date of Award”:
November     , 2009 
 “Number of Shares”:
                        . 
 We are pleased to inform you that the Compensation Committee of our Board of Directors (the “Committee”) has decided to grant you an award (your “Award”) of
our Common Stock (the “Common Stock”) under our 2007 Equity Incentive Plan (the “Plan”). You will be entitled to receive one third (33 1/3%) of the Number of Shares set forth above as of each of first
three anniversaries of the Date of Award if you have been continuously employed by, or are a director of, Learning Tree or its subsidiaries through such date. You will not have any right to receive or be issued any shares of Common Stock
under this Award (i) if Learning Tree does not report an operating profit for its 2010 fiscal year or (ii) with respect to any issuance scheduled to occur after you cease to be an employee or director of Learning Tree or one of its
subsidiaries (whether voluntarily or involuntarily). 
 Please review the Plan and the attached Standard Terms and Conditions
carefully, as they control your rights under your Award. Then sign (and if you are married, have your spouse sign) one copy of this letter and return it to Nancy McKinley. If you have any questions, please call her. 
 We appreciate your continuing efforts on behalf of Learning Tree. 
  

			
	Very truly yours,
	Learning Tree International, Inc.
		
	By:	 	  

		
	Its:	 	  

 I hereby accept this Award and have reviewed the Plan and the Terms. I understand that I will
not receive the shares of stock involved under certain circumstances, including my ceasing to be an employee of Learning Tree, whether voluntarily or not. I further understand that I may not transfer my Award except under circumstances described in
the Plan. 
  

	
	  

	“Grantee”

 Consent by Grantee’s Spouse: I agree to be bound by all of the terms and conditions
of the Award, including those set forth in the Plan and the Terms. 
  

					
	  
	 		 	  

	 signature
	 		 	 print name

 STANDARD TERMS AND CONDITIONS 
 These Standard Terms and Conditions are attached to a letter granting a stock award to you (the “Award Letter”) from Learning Tree
International, Inc. (“Learning Tree”). The Award Letter, these Standard Terms and Conditions and Learning Tree’s 2007 Equity Incentive Plan (the “Plan”) are collectively the “Award
Documents”. Capitalized terms not defined in these Standard Terms and Conditions are defined in the Award Letter or the Plan. 
 1. Issuance of Certificate. Subject to the Award Documents, Learning Tree will issue to you (or following your death, your estate) a certificate of any shares due under this Award promptly
after they vest. No consideration will be due for the issuance of those shares, although you will be responsible for any withholding taxes. In the event of any stock split, stock dividend, recapitalization, reorganization, merger, consolidation,
combination, exchange of shares, liquidation, spin-off or other similar change in capitalization or event, or any distribution to holders of Shares other than a cash dividend, the number and class of securities subject to the Award shall be
appropriately adjusted by the Committee. The decision of the Committee regarding any such adjustment shall be final, binding and conclusive. Learning Tree shall not be required to issue fractional shares of Common Stock upon settlement of this
Award. 
 2. Withholding of Taxes. Upon request by Learning Tree, the person entitled to the Shares shall pay
Learning Tree the amount of any taxes which Learning Tree is required to withhold. If such payment is not made when requested, Learning Tree may, in its discretion, refuse to issue the certificate for the Shares, sell the Shares to obtain such
amount, or deduct any such payment from any amount then or thereafter payable by Learning Tree or a Subsidiary or pursue any other available remedy. 
 3. Shares to be Issued in Compliance with Applicable Laws and Exchange Rules. You represent and agree that this Award is not being acquired with a view to any sale, transfer or distribution
in violation of any applicable securities laws or regulations. If required by the Committee, you shall furnish evidence satisfactory to Learning Tree to such effect (including a written representation and an indemnification of Learning Tree in the
event of any violation of any applicable laws). 
 4. No Assignment or Transfer. This Award may not be
transferred, either voluntarily or by operation of law except (i) by will or the laws of descent and distribution or (ii) to your designated beneficiary to the extent permitted by the Committee. Any other attempt to transfer this Award
will cause this Award and all rights and privileges granted hereby to immediately become null and void and be of no further force or effect. 
 5. Not an Employment or Service Contract. Nothing in this Award is to be construed as an agreement, express or implied, by Learning Tree or any of its subsidiaries to employ you or contract
for your services, nor will it restrict Learning Tree’s or such subsidiary’s right to discharge you or cease contracting for your services or to modify, extend or otherwise affect in any manner whatsoever, the terms of any employment
agreement or contract for services which may exist between you and Learning Tree or any of its subsidiaries. This Award will not affect any right you might otherwise have to participate in and receive benefits under the then current provisions of
any pension, insurance, or profit sharing program of Learning Tree or any of its subsidiaries. 
 6. No Rights as a
Shareholder Until Issuance of Stock Certificate. Neither you nor any other person will be entitled to any of the rights or privileges of a shareholder of Learning Tree with respect to any shares issuable under this Award unless and until a
certificate or certificates representing the shares shall have been actually issued and delivered. 
 7. Agreement Subject
to Plan. The Plan is incorporated herein by reference. This Award is subject to, and Learning Tree and you agree to be bound by, all of the terms and conditions of the Plan, as it may be amended from time to time in accordance with its
terms. No amendment to the Plan will adversely affect your rights under this Award in a material manner without your prior written consent. 
 8. Tax Effect of Payments. In the event that it is determined that any Shares or payment under this Award would subject any payments to the excise tax imposed by Section 4999 or
Section 409A of the Code or any interest or penalties with respect to such excise tax (such excise tax, together with any such interest or penalties, are collectively referred to as the “Excise Tax”), then this Award
shall be interpreted and modified by the Committee to provide as near as possible the same economic benefit to you hereunder but without triggering any Excise Tax, and any clause which the Committee determines would otherwise trigger such a tax will
be null and void. 
 9. Entire Agreement; Governing Law. The Award Documents constitute our entire agreement with
respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of Learning Tree and you with respect to the subject matter hereof. The interpretation, performance and enforcement of this Agreement shall be
governed by the internal substantive laws of the State of Delaware, without regard to the conflict of laws provisions of that or any other State. The Award Documents can only be amended in a writing executed by a duly authorized Executive Officer of
Learning Tree.Amendment No. 2, effective July 8, 2009

 Exhibit 10.1 
 [********] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. 
 AMENDMENT NO. 2 TO 
 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT 
 This Amendment No. 2 to Collaborative Research and License Agreement (this “Amendment”), effective as of the date of signature of the last Party to sign below, amends the
Collaborative Research and License Agreement entered into as of December 27, 2005 by and between AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden (“AstraZeneca”), and Targacept, Inc.,
a Delaware (USA) corporation (“Targacept”), as amended by Amendment No. 1 dated November 10, 2006 (the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed
to them in the Agreement. 
 WHEREAS AstraZeneca has completed two Phase II Clinical Trials of Ispronicline, one in AD and one
in CDS, neither of which resulted in the occurrence of Achievement of Proof of Concept; 
 WHEREAS the Parties have collaborated
to conduct a Phase II Clinical Trial of Ispronicline in ADHD funded by Targacept and, following such trial, AstraZeneca plans to continue Development of Ispronicline; and 
 WHEREAS AstraZeneca and Targacept desire to amend the Agreement in accordance with Section 17.6 thereof to reflect certain additional or modified terms that shall be or may become applicable to the
continued Development of Ispronicline. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein and for
other good and valuable consideration, AstraZeneca and Targacept, intending to be legally bound, hereby agree as follows: 
 1. The Agreement is
hereby amended by adding the following to the end of Section 6.5.1(a) as the last paragraph. 
 “The terms of this
Section 6.5.1(a) shall be subject to the terms of Section 6.7, if and to the extent applicable.” 
 2. The Agreement is hereby
amended by adding the following new Section 6.7. 
 “6.7 Ispronicline ADHD Development Terms. Each of
the Parties hereby agrees as follows. 
 (a) As a result of the achievement of the objective in the completed Phase II Clinical
Trial of Ispronicline in ADHD funded by Targacept, AstraZeneca shall make a milestone payment to Targacept as contemplated by the Parties prior to initiation of such trial, such milestone payment to be in the amount of $10 million and non-creditable
and non-refundable. 
 (b) With respect to each of milestone event 4 through milestone event 9 (six milestone events) under the
heading “Milestone Event” in Section 6.5.1(a) for Ispronicline/ Ispronicline Products (column A) (reproduced under the heading “Milestone Event” below), if the applicable Primary Indication for the first occurrence of such
milestone event is ADHD (a “Subject ADHD Milestone Event”), then the amount payable to Targacept by AstraZeneca with respect to such Subject ADHD Milestone Event shall be the amount shown below corresponding to such milestone event,
if any (and, for clarity, not the amount shown in Section 6.5.1(a), column A, corresponding to such milestone event), subject to Section 6.7(c). 

			
	 Milestone Event
	  	Amount
		
	 4. [********] of [********]
	  	[********]
		
	 5. Initiation of [********]
	  	[********]
		
	 6. [********] of [********]
	  	[********]
		
	 7. First Commercial Sale [********]
	  	[********]
		
	 8. First Commercial Sale [********]
	  	[********]
		
	 9. First Commercial Sale [********]
	  	[********]

 (c) With respect to each Subject ADHD Milestone Event, the first time that the same
milestone event as such Subject ADHD Milestone Event occurs for Ispronicline or an Ispronicline Product where the applicable indication is any one of Schizophrenia or any Primary Indication besides ADHD (the “Corresponding PI Milestone
Event”), AstraZeneca shall, within thirty (30) days of such Corresponding PI Milestone Event, make a non-creditable, nonrefundable payment to Targacept in an amount equal to the positive difference between (i) the amount payable
under Section 6.5.1(a), column A, with respect to the Corresponding PI Milestone Event as if the occurrence of the Corresponding PI Milestone Event had been the first occurrence of such milestone event (and, for clarity, had preceded the
occurrence of the Subject ADHD Milestone Event) and (ii) the amount paid or payable by AstraZeneca with respect to the Subject ADHD Milestone Event in accordance with Section 6.7(b). For clarity, with respect to each Subject ADHD Milestone
Event, there can be no more than one (1) Corresponding PI Milestone Event and, as a result, there can be no more than six (6) Corresponding PI Milestone Events in the aggregate. 
 (d) For clarity: (i) Sections 6.7(b) and 6.7(c) shall apply solely to the application of Section 6.5.1(a) to Ispronicline and
Ispronicline Products under the circumstances described therein and for no other purpose (for further clarity, Sections 6.5.1(b) and 6.5.1(c) and the amounts payable to Targacept by AstraZeneca thereunder, if any, are not intended to be affected by
this Section 6.7); (ii) any payment obligation of AstraZeneca that arises under Section 6.7(b) or Section 6.7(c) shall be deemed to arise under Section 6.5.1(a) and therefore subject to Sections 6.5.1(a)
(excluding the dollar amounts shown in the table therein), 6.5.2, 6.6.1(d)(2), 10.2.4 and 10.2.6 (in each case if and to the extent applicable), except as provided in clause (iv) below; (iii) amounts paid to Targacept by
AstraZeneca under Section 6.7(b) or Section 6.7(c) shall be deemed paid under Section 6.5.1(a); and (iv) no payment made by AstraZeneca pursuant to Section 6.7 shall be deemed to violate or be inconsistent with the
provisions of Section 6.5.1(a) or any other provision of the Agreement that may restrict the number of times AstraZeneca will make a payment corresponding to any particular milestone event with respect to Ispronicline or an Ispronicline Product
under Section 6.5.1(a).” 

 3. Except as expressly amended by this Amendment, all of the terms and conditions of the Agreement shall
remain in full force and effect. This Amendment is not intended and shall not be construed to change AstraZeneca’s diligence obligations as set forth in the Agreement (including, without limitation, Section 5.5.1 (AstraZeneca Diligence
Obligations)). 
 4. AstraZeneca shall pay to Targacept the milestone payment required by Section 6.7(a) of the Agreement, as amended, on
or before the fifth (5th) Business Day after the effective date of this Amendment. 
 [Remainder of page intentionally
left blank.] 

 IN WITNESS WHEREOF AstraZeneca and Targacept have executed this Amendment as of the respective dates set
forth below. 
  

									
	TARGACEPT, INC.	 		 	ASTRAZENECA AB (publ.)
					
	By:	 	 /s/ J. Donald deBethizy
	 		 	By:	 	 /s/ Jan M. Lundberg

	Name:	 	J. Donald deBethizy	 		 	Name:	 	Jan M. Lundberg
	Title:	 	President and CEO	 		 	Title:	 	President
	Date:	 	July 8, 2009	 		 	Date:	 	July 6, 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]